Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Antex Biologics (ANTX) -- Ignore unavailable to you. Want to Upgrade?

To: lostmymoney who wrote (819)	4/2/1998 9:24:00 AM
From: F. Jay Abella, III	Read Replies (1) \| Respond to of 1476

Hi All: Someone 20 posts back wrote - <<<<"I just finished reviewing Pre 14A released by ANTX today at the following site- freeedgar.com It says they are to discuss either a 1 for 10 or a 1 for 4 reverse stock split at their meeting on June 8. I have not had good results in stocks I've owned in the past who have had reverse splits Do you feel that this will negatively effect the stock value? Any input would be appreciated.">>>> My 0.02 is that the company's first priority this year is to get off the bulletin board. Nasdaq (or better yet, AMEX) listing would do wonders for the market conditions for ANTX. It would also take care of some of the internal compliance issues rightly mentioned in another post (especially if the stock can be adjusted to over $5.00 post split). This involves at least a 1 to 5 reverse of fully diluted shares (approx 30mm), leaving 6mm or so out there. Recall, many of these shares would still be in the float, so a shortage may not ensue. However, if the reverse spilt is supplemented with positive clinical results, you might see some of the shares vanish into institutional hands. I like that scenario very much, but admittedly makes liquidity more of an issue than it is at present.